Addressing the challenges of infectious disease testing and other areas of unmet diagnostic need such as antibiotic resistance
Mobidiag is a commercial stage, fast-growing Finnish-French biotechnology company, offering innovative molecular diagnostics. We specialise in the development and marketing of fast, reliable and cost-effective molecular innovative diagnostic solutions for Gastrointestinal Infections, Antimicrobial Resistance Management, Hospital Associated Infections (HAIs), Respiratory Infections (including COVID-19) and Sepsis.
A word from Mobidiag CEO, Tuomas Tenkanen:
"At Mobidiag, we are addressing a significant global health challenge while offering innovative molecular diagnostics:
- The global demand for diagnosing infectious diseases is increasing. However available diagnostic solutions do not fully meet the current needs of clinical laboratories and the health care industry.
- The alarming rise of antimicrobial resistance (AMR): by 2050, 10 million people could die each year due to the spread of multidrug resistant organisms ("superbacteria") and the lack of treatment available, which is more than the current rates for cancer and diabetes combined (1).
- Traditional diagnostic methods are generally cheap but time-consuming, labour intensive and lacking in sensitivity, while new molecular diagnostic solutions are fast and easy to use, but expensive. This obvious gap in the market is the space which Mobidiag aims to fill.
- In addition to this, infectious diseases represent a large portion of the current market given the re-emergence of infectious threats.
The investors page aims at presenting Mobidiag achievements and performances. In addition, it will bring you further insights on our core business in the field of in vitro diagnostics. Feel free to browse through the available material.
If you have any questions, contact us and we would be more than happy to discuss latest Corporate highlights and Mobidiag's positioning in offering innovative molecular diagnostics .
2021
17/06: Hologic Completes Acquisition of Mobidiag
2020
16/06: Mobidiag Receives Second Tranche of €25M Financing from EIB
07/01: Mobidiag Secures Additional Funding from Business Finland for Rapid Sepsis Diagnostic Test
2019
10/12: Mobidiag Appoints Joseph Bernardo as Senior Strategic Advisor
03/06: Mobidiag announces launch of Automobi Molecular Diagnostics
14/05: Mobidiag secures EUR 25 million from European Investment Bank
04/02: Mobidiag announces completion of €10m equity investment from Autobio Diagnostics
2018
17/12: Mobidiag Announces Joint Venture with Autobio Diagnostics and €10m equity investment
15/11: Mobidiag Receives Final €4M Tranche of €15M EIB Financing
24/05: Mobidiag Secures Additional €4 Million in Capital Increase with Springvest´s Public Financing Round
14/04: Novodiag Bacterial GE+, a new diagnostic test for on-demand detection of bacterial pathogens
03/01: Novodiag® launch, a new diagnostic solution for infectious diseases
2017
21/12: Novodiag® launch, a new diagnostic solution for infectious diseases
18/04: Mobidiag Secures Additional 3,99 Million Euros from Kansalaisrahoitus’ Public Financing Round
17/01: Mobidiag to Offer Amplidiag® Diagnostics Products in South Africa
2016
29/08: Mobidiag Announces Release of Amplidiag Stool Parasites
23/06: Mobidiag_Announces_Distribution_Agreement_with_Isogen_Life_Science